Non-Small Cell Lung CancerPhase 2QS-NSCLCNCT07845916
Quad Shot Radiotherapy Combined With Tislelizumab and Platinum-Based Chemotherapy Before Surgery for Stage II-III Non-Small Cell Lung Cancer
A Phase 2 study testing Quad Shot Radiotherapy, Tislelizumab and Carboplatin or cisplatin in people with Non-Small Cell Lung Cancer, run by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology at 1 site in China.
Trial summary
This study aims to evaluate a new pre-surgery (neoadjuvant) treatment for patients with stage II-III non-small cell lung cancer (NSCLC). Currently, standard pre-surgery treatment involves immunotherapy combined with chemotherapy. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Non-Small Cell Lung Cancer
- What is being tested?
- Quad Shot Radiotherapy, Tislelizumab and Carboplatin or cisplatin
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 12 participants
- Where
- 1 siteChina
- Study dates
- 10 Oct 2026to 31 Dec 2031
- Phase
- Phase 2
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 18-75 years, either gender.
- Histologically or cytologically confirmed, untreated stage II-IIIB non-small cell lung cancer (NSCLC) (including T3-4N2 IIIB, AJCC 9th edition). Baseline staging must include PET/CT (or chest + upper abdomen contrast-enhanced CT + whole body bone scan) + brain MRI. Stage III patients will be further subdivided into IIIA and IIIB per AJCC 9th edition for separate recording, evaluation, and analysis.
- Evaluated as resectable by a multidisciplinary team including thoracic surgeons.
- At least one evaluable target lesion per RECIST v1.1.
- ECOG Performance Status 0-1.
- Adequate major organ function: Neutrophils ≥ 1.5×10^9/L; Platelets ≥ 100×10^9/L; Hemoglobin > 9.0 g/dL; Serum creatinine ≤ 1.5×ULN or Creatinine Clearance (CrCl) ≥ 40 mL/min; AST/ALT ≤ 3×ULN; Total bilirubin ≤ 1.5×ULN; INR/APTT within normal range; FEV1 ≥ 1.2L or > 40% predicted.
Show all 9Show fewer
- Signed written informed consent prior to any study-related procedures.
- Investigator judges that the patient is able to comply with the study protocol, willing and able to follow visit schedules, treatment plans, laboratory tests, and other study procedures.
- Negative pregnancy test at screening (for women of childbearing potential). Subjects of childbearing potential (male and female) must agree to use effective contraception from screening until 180 days after the last dose.
Who cannot join
- Known or suspected autoimmune disease (except vitiligo, Type I diabetes, or hypothyroidism requiring only hormone replacement therapy with no signs of recurrence).
- Requires systemic corticosteroid therapy (>10 mg/day prednisolone or equivalent) or other immunosuppressive drugs within 14 days prior to enrollment (inhaled or topical steroids, and physiological replacement doses of adrenal corticosteroids are allowed).
- History of thoracic radiotherapy.
- Active bleeding before treatment.
- Severe heart, lung, liver, or kidney dysfunction, hematopoietic system disease, cachexia, or other conditions that make the patient unable to tolerate chemoradiotherapy.
- History of diabetes for more than 10 years with unsatisfactory blood glucose control.
Show all 16Show fewer
- History of interstitial lung disease or non-infectious pneumonitis.
- NSCLC patients with EGFR sensitizing mutations or ALK fusion genes.
- Prior or concurrent other malignancies (except cured non-melanoma skin cancer and carcinoma in situ; or malignancies in complete remission for ≥ 2 years without requiring additional anti-tumor therapy during the study period).
- Prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4, or other drugs targeting T-cell costimulatory or immune regulatory pathways.
- Active hepatitis B (HBV DNA ≥ 2000 IU/mL or 10^4 copies/mL) or hepatitis C (HCV antibody positive and HCV-RNA above the lower limit of detection).
- HIV positive or diagnosed with acquired immunodeficiency syndrome (AIDS).
- Received live vaccine within 4 weeks prior to the start of study treatment.
- Known or suspected allergy to the study drugs or any related drugs in this trial.
- Pregnant or breastfeeding women.
- Investigator considers that the patient has other factors that may prevent completion of the study or affect subject safety or data collection.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site
Wuhan Union Hospital
Wuhan, Hubei, 430022
Kunyu Yang, MD, 13995595360, yangkunyu@hust.edu.cn
About this study
Official title: A Single-Arm, Prospective, Exploratory Phase II Clinical Study of Quad Shot Radiotherapy Combined With Tislelizumab and Platinum-Based Doublet Chemotherapy as Neoadjuvant Treatment for Stage II-III Non-Small Cell Lung Cancer
This study aims to evaluate a new pre-surgery (neoadjuvant) treatment for patients with stage II-III non-small cell lung cancer (NSCLC). Currently, standard pre-surgery treatment involves immunotherapy combined with chemotherapy. While effective, many patients still have residual tumor cells after this standard treatment.
Radiation therapy can not only kill tumor cells but also help the immune system recognize and fight cancer. The type of radiation used in this study is called "Quad Shot" (QS) radiotherapy. It is a short, high-dose, cyclical treatment designed to boost the effects of immunotherapy with less toxicity than standard daily radiation.
Patients in this study will receive 3 cycles of QS radiotherapy combined with Tislelizumab (an immunotherapy drug) and standard platinum-based chemotherapy before surgery. The main goal of this study is to see if this combined approach can make the tumor completely disappear under a microscope (called pathological complete response, or pCR). Researchers will also monitor the safety of the treatment, side effects, and how well patients tolerate the treatment before undergoing surgery. Approximately 12 patients will be enrolled in this study.
Read the detailed description
Background:
Neoadjuvant immune checkpoint inhibitor (ICI) combined with platinum-based chemotherapy has become a standard of care for resectable stage II-III NSCLC, as demonstrated by phase III trials such as CheckMate-816, KEYNOTE-671, and RATIONALE-315. However, a significant proportion of patients still fail to achieve deep pathological responses due to mechanisms such as poor antigen release, impaired antigen presentation, and an immunosuppressive tumor microenvironment (TME).
Radiotherapy possesses immunomodulatory properties, inducing immunogenic cell death and promoting antigen release. However, traditional continuous fractionated radiotherapy may deplete circulating lymphocytes and cause normal tissue damage. The "Quad Shot" (QS) regimen is a cyclical hypofractionated radiotherapy approach (14-14.8 Gy in 4 fractions over 2 days) that has shown low toxicity in palliative settings. Its cyclical, pulsatile nature may provide repeated immune stimulation and TME remodeling, making it a promising partner for immunotherapy.
Study Design:
This is a single-arm, prospective, exploratory phase II clinical study. Patients with histologically or cytologically confirmed, untreated, resectable stage II-IIIB NSCLC (including T3-4N2 IIIB, AJCC 9th edition) will be enrolled.
Patients will receive 3 cycles of neoadjuvant treatment (every 3 weeks):
Quad Shot radiotherapy (14-14.8 Gy/4 fractions, Day 1-2) Tislelizumab (200 mg, Day 3) Platinum-based doublet chemotherapy (Day 3): Carboplatin (AUC 5) or Cisplatin (75 mg/m²) combined with Pemetrexed (500 mg/m², for non-squamous) or Paclitaxel (175 mg/m², for squamous).
Following 3 cycles of neoadjuvant therapy, patients will undergo surgery 4-6 weeks (±7 days) after the last dose. Postoperative adjuvant therapy will be administered at the investigator's discretion according to NCCN and CSCO guidelines.
Objectives and Endpoints:
The primary objective is to evaluate the antitumor efficacy of this regimen, with the primary endpoint being the pathological complete response (pCR) rate. Secondary endpoints include major pathological response (MPR) rate, R0 resection rate, objective response rate (ORR) per RECIST v1.1, event-free survival (EFS), overall survival (OS), safety (NCI CTCAE v5.0), feasibility, surgical complications (Clavien-Dindo classification), and QS radiotherapy-related toxicities.
Sample Size:
A total of 12 patients will be enrolled, with at least 10 evaluable patients included in the primary endpoint analysis to account for an estimated 2 dropouts.
Study Duration:
The estimated enrollment period is 6-12 months, with an anticipated study completion date of December 2031.
- Conditions
- Non-Small Cell Lung Cancer
- Being tested
- Quad Shot Radiotherapy, Tislelizumab, Carboplatin or cisplatin, Pemetrexed or Paclitaxel
- Keywords
- NSCLC, Neoadjuvant Therapy, Quad Shot Radiotherapy, Tislelizumab, Platinum-based Chemotherapy, Immunotherapy, Pathological Complete Response
- Medical subject headings
- Carcinoma, Non-Small-Cell Lung
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Quad Shot RadiotherapyRadiation
3.7 Gy per fraction, twice daily (with an interval of at least 6 hours), for 4 fractions over 2 consecutive days (Days 1-2 of each cycle). Total dose of 14.8 Gy per cycle, repeated every 3 weeks for 3 cycles (cumulative dose 44.4 Gy). Delivered using IMRT or VMAT.
TislelizumabDrug
200 mg administered via intravenous infusion on Day 3 of each 21-day cycle for 3 cycles.
Carboplatin or cisplatinDrug
Carboplatin (AUC 5) or Cisplatin (75 mg/m²) administered intravenously on Day 3 of each 21-day cycle for 3 cycles.
Pemetrexed or PaclitaxelDrug
Pemetrexed (500 mg/m²) for non-squamous NSCLC or Paclitaxel (175 mg/m²) for squamous NSCLC, administered intravenously on Day 3 of each 21-day cycle for 3 cycles.
| Study group | Role | What they receive |
|---|---|---|
| Neoadjuvant Quad Shot Radiotherapy + Tislelizumab + Chemotherapy | Experimental | Patients receive 3 cycles of neoadjuvant therapy (every 21 days). Each cycle consists of:
* Quad Shot radiotherapy (14-14.8 Gy/4 fractions on Day 1-2)
* Tislelizumab (200 mg, Day 3)
* Platinum-based doublet chemotherapy (Day 3): Carboplatin (AUC 5) or Cisplatin (75 mg/m²), combined with Pemetrexed (500 mg/m² for non-squamous) or Paclitaxel (175 mg/m² for squamous).
Surgery is performed 4-6 weeks (±7 days) after the third cycle. Postoperative adjuvant therapy is administered at the investigator's discretion according to NCCN and CSCO guidelines. Receives: Radiation: Quad Shot Radiotherapy; Drug: Tislelizumab; Drug: Carboplatin or cisplatin; Drug: Pemetrexed or Paclitaxel |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pathological Complete Response (pCR) Rate
The proportion of patients with no residual viable tumor cells in the resected primary tumor and regional lymph nodes, as assessed by pathological review. Patients who do not undergo surgery will be considered as not achieving pCR.
Measured: After completion of neoadjuvant therapy and surgery (approximately 4-6 weeks after the last dose of neoadjuvant therapy)
Secondary outcomes (8)
Major Pathological Response (MPR) Rate
The proportion of patients with ≤10% viable tumor cells in the resected specimen.
Measured: After completion of neoadjuvant therapy and surgery (approximately 4-6 weeks after the last dose of neoadjuvant therapy)
R0 Resection Rate
The proportion of patients achieving microscopically margin-negative resection.
Measured: At time of surgery
Objective Response Rate (ORR) per RECIST v1.1
The proportion of patients achieving a confirmed complete or partial response according to RECIST v1.1.
Measured: Up to 14 days before surgery
Event-Free Survival (EFS) and 2-Year EFS Rate
Time from enrollment to disease progression, local recurrence, distant metastasis, or death from any cause.
Measured: Up to 60 months after enrollment
Overall Survival (OS) and 2-Year OS Rate
Time from enrollment to death from any cause.
Measured: Up to 60 months after enrollment
Incidence and Severity of Adverse Events (AEs), Serious Adverse Events (SAEs), and Immune-Related Adverse Events (irAEs)
Evaluated according to NCI CTCAE v5.0.
Measured: From informed consent to 90 days after the last dose of study treatment
Feasibility (Completion Rate of Neoadjuvant Therapy and Surgery)
Proportion of patients completing 3 cycles of neoadjuvant therapy and undergoing surgery as planned; surgical delay rate.
Measured: Up to 4-6 weeks after the last dose of neoadjuvant therapy
QS Radiotherapy-Related Toxicity
Incidence and severity of radiation pneumonitis, esophagitis, dermatitis, myelosuppression, and myocarditis, graded according to NCI CTCAE v5.0.
Measured: Up to 90 days after the last dose of radiotherapy
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Sep 2026
- Study start10 Oct 2026 (estimated)
- Primary completion30 Jun 2027 (estimated)
- Study completion31 Dec 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Non-Small Cell Lung CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 12 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07845916
- Sponsor's protocol ID
- QS-NSCLC-2026-01
- Acronym
- QS-NSCLC
- Status last verified
- Sep 2026
- First submitted
- 21 Sep 2026
- Last updated
- 29 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No